Tag Archives: NASDAQ:ADMP

Maxim Group Reaffirms Their Buy Rating on Adamis Pharma (ADMP)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP) today and set a price target of $13. The company’s shares opened today at $3.90. McCarthy noted: “Adamis announced FDA approval of Symjepi Jr. (15 mg)

Adamis Pharma (ADMP) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP) today and set a price target of $13. The company’s shares opened today at $3. McCarthy noted: “The PDUFA date for Symjepi jr. (0.15mg) is approaching

H.C. Wainwright Thinks Adamis Pharma’s Stock is Going to Recover

In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP). The company’s shares closed yesterday at $2.75, close to its 52-week low of $2.20. Kolbert commented: “EpiPen as an Exchange NASDAQ

Analysts Are Bullish on Top Healthcare Stocks: Adamis Pharma (ADMP), TG Therapeutics (TGTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adamis Pharma (NASDAQ:ADMP) and TG Therapeutics (NASDAQ:TGTX) with bullish sentiments. Adamis Pharma (ADMP) In a report issued on August 10, Andrew D’silva

Maxim Group Maintains Their Buy Rating on Adamis Pharma

Maxim Group analyst Jason McCarthy maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP) today and set a price target of $10. The company’s shares opened today at $3.80. McCarthy noted: “Adamis reported 1Q18 with revenue of $3.2M from the

Adamis Pharma Gets a Buy Rating from B.Riley FBR

In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP), with a price target of $6.25. The company’s shares closed yesterday at $3.50. D’silva wrote: “We are updating our model on